Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Obstetrix Medical Group |
---|---|
Information provided by: | Obstetrix Medical Group |
ClinicalTrials.gov Identifier: | NCT00163020 |
Hypothesis: Among women with twin or triplet pregnancies, weekly injections of 17-alpha-hydroxyprogesterone caproate (17OHP), started before 24 weeks of gestation, will reduce neonatal morbidity by reducing the rate of preterm delivery.
This study involves two concurrent double-blinded randomized clinical trials of 17OHP versus placebo. Each trial will test the efficacy and safety of 17OHP in women with a specific risk factor for preterm birth. The two risk factors to be studied are:
Condition | Intervention | Phase |
---|---|---|
Preterm Birth |
Drug: 17-alpha-hydroxyprogesterone caproate injectable Drug: Placebo |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | 17-Alpha-Hydroxyprogesterone Caproate for Reduction of Neonatal Morbidity Due to Preterm Birth in Twin and Triplet Pregnancies - A Concurrent Randomized Double-blinded Clinical Trial |
Estimated Enrollment: | 321 |
Study Start Date: | November 2004 |
Estimated Study Completion Date: | February 2010 |
Estimated Primary Completion Date: | January 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1 Test Group (170HP): Active Comparator
Test Group will receive weekly doses of 170HP via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
|
Drug: 17-alpha-hydroxyprogesterone caproate injectable
250mg of 17-alpha-hydroxyprogesterone caproate (+ preservatives) injectable weekly starting as early as 19wks gestation until 34.0wks gestation of delivery which ever comes first.
|
2 - Control (Normal Saline): Placebo Comparator
Control Group will receive weekly doses of placebo (NS) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
|
Drug: Placebo
Weekly doses of placebo (NS + preservatives) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
|
Prematurity is a leading cause of neonatal morbidity and mortality in the USA. Nationally, 12% of all babies deliver before term and 3% deliver before 32 wks gestational age (GA). Recent studies suggest that 17OHP and other progesterone derivatives may reduce the rate of preterm birth among women with a history of prior preterm birth. However, it has not been demonstrated that this reduction in preterm birth is accompanied by a clinically significant reduction in neonatal complications. Further, most women who deliver preterm have no history of a prior preterm birth. Little is known about whether progesterone treatment is effective in women with other risk factors for preterm birth such as multiple gestation. The proposed study will assess the role of 17OHP in women with twin or triplet pregnancies and will assess the impact on neonatal health, not merely the impact on gestational age at delivery. Prior studies were not designed to be large enough to have statistical power to assess effects on neonatal morbidity.
In the 6 trials combined in the Goldstein meta-analysis, only 279 women were treated with 17OHP and only 73 women had a preterm delivery. The NICHD study presented by Meis approximately doubles the world-wide experience, with 306 women under treatment, of whom 73 delivered prior to 35 wks. Yet, this study was not designed to have power to show a reduction in neonatal complications but only a reduction in preterm birth rates.
The present study is the first to be specifically designed to have adequate power to test whether 17OHP reduces neonatal morbidity among women with one of two specific risk factors for preterm birth.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
One of these risk factors for spontaneous preterm birth:
Exclusion Criteria:
Preexisting maternal medical condition associated with a high risk of preterm delivery including:
refractory hypertension, diabetes with nephropathy or retinopathy, renal insufficiency, active systemic lupus erythematosus. Note that a history of prior preterm birth is NOT an exclusion.
United States, Arizona | |
Banner Good Samaritan Hospital | |
Phoenix, Arizona, United States, 85006 | |
Desert Good Samaritan Hospital | |
Mesa, Arizona, United States, 85202 | |
Tucson Medical Center | |
Tucson, Arizona, United States, 85712 | |
United States, California | |
Good Samaritan Hospital | |
San Jose, California, United States, 95124 | |
Long Beach Memorial Medical Center | |
Long Beach, California, United States, 90801-1428 | |
Saddleback Memorial Medical Center | |
Laguna Hills, California, United States, 92653 | |
University of Southern California-Irvine Medical Center | |
Orange, California, United States, 92868 | |
United States, Colorado | |
Presbyterian/St Luke's Hospital | |
Denver, Colorado, United States, 80218 | |
Swedish Medical Center | |
Denver, Colorado, United States, 80110 | |
Rose Medical Center | |
Denver, Colorado, United States, 80220 | |
Skyridge Medical Center | |
Lonetree, Colorado, United States, 80124 | |
United States, Iowa | |
Mercy Medical Center | |
Des Moines, Iowa, United States, 50314 | |
United States, Missouri | |
Saint Luke's Hospital, Kansas City | |
Kansas City, Missouri, United States, 64111 | |
United States, Tennessee | |
Erlanger Medical Center | |
Chattanooga, Tennessee, United States, 37403 | |
United States, Texas | |
Harris Methodist Fort Worth Hospital | |
Fort Worth, Texas, United States, 76104 | |
Baylor University Medical Center | |
Dallas, Texas, United States, 75246 | |
United States, Washington | |
Swedish Medical Center | |
Seattle, Washington, United States, 98122-4307 | |
Evergreen Hospital | |
Kirkland, Washington, United States, 98034 |
Study Director: | Kimberly Maurel, RN, MSN, CNS | Obstetrix Medical Group, Inc. |
Principal Investigator: | Andrew Combs, MD | Obstetrix Medical Group, Inc. |
Responsible Party: | Obstetrix Medical Group, Inc. ( Kimberly Maurel ) |
Study ID Numbers: | OBX0003, IND # 59-536 |
Study First Received: | September 9, 2005 |
Last Updated: | August 20, 2009 |
ClinicalTrials.gov Identifier: | NCT00163020 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Preterm Birth Preterm Delivery Multiple gestation 17-alpha-hydroxyprogesterone caproate Progesterone |
Estrogen Antagonists Estrogens Pregnancy Complications Progesterone Obstetric Labor, Premature Hormone Antagonists Caproate Estradiol valerate Obstetric Labor Complications Hormones, Hormone Substitutes, and Hormone Antagonists |
Estradiol 17 beta-cypionate Hormones Estradiol 17-alpha-hydroxy-progesterone caproate Estrogen Receptor Modulators Progestins Estradiol 3-benzoate Polyestradiol phosphate Premature Birth |
Estrogen Antagonists Pregnancy Complications Hormone Antagonists Obstetric Labor, Premature Physiological Effects of Drugs Obstetric Labor Complications Hormones, Hormone Substitutes, and Hormone Antagonists |
Hormones 17-alpha-hydroxy-progesterone caproate Pharmacologic Actions Estrogen Receptor Modulators Progestins Estradiol Antagonists Premature Birth |